A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin
December 4, 2025
Source: drugdu
44
Recently, Kingfriend Pharmaceutical Co., Ltd.The company announced that it recently received notification from the U.S. Food and Drug Administration (FDA) that its Chengdu subsidiary, Jianjin Pharmaceutical Co., Ltd., has officially approved the injectable dapavancin for sale in the United States. The first batch of products was shipped to the U.S. under controlled conditions in early November.
According to reports, dapavancin for injection is primarily used to treat acute bacterial skin and skin structure infections in adults and pediatric patients. Related data shows that in 2024, the drug's market size in the United States exceeded $250 million, while no similar products have yet been approved in the Chinese market. Kingfriend Pharmaceutical stated that this approval not only further enriches its product pipeline in the US market but also makes Kingfriend Pharmaceutical the first domestic company to obtain international approval for this product.
https://finance.eastmoney.com/a/202512023580381538.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
- Self-developed innovative drug FXS0887 approved for clinical trials in advanced malignant solid tumors December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
